enGene Holdings Inc. Common Stock (ENGN NASDAQ) stock market data APIs
$1.7315
0.4(23.1%)
as of May 7, 2026
Try our APIs with
free plan!
enGene Holdings Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Prev. Close
1.7315
Open
2.1347
High
2.2584
Low
1.7017
52 wk Range
1.7-12.25
Market Cap
593 M
Shares Outstanding
66 989 K
EPS
-0.44
Beta
-0.01
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get enGene Holdings Inc. Common Stock data using free add-ons & libraries
Get enGene Holdings Inc. Common Stock Fundamental Data
enGene Holdings Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -127 141 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get enGene Holdings Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-09
- EPS/Forecast: -0.5738
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
enGene Holdings Inc. Common Stock News
New
Bristol-Myers Squibb Company (BMY): Favorite for Conservative Portfolios
We just covered the 14 Best Defensive Stocks to Invest In Now and Bristol-Myers Squibb Company (NYSE:BMY) ranks 5th on this list. Bristol-Myers Squibb Company (NYSE:BMY) remains a favorite for conser...
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)...
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics(NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. What happened A...
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
enGene logo Key Points Protocol amendments—T1 re-resection, TA reinduction, and requiring biopsy confirmation—plus reinduction of nonresponders contributed to improved response rates, and manage...
Get enGene Holdings Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
